Confluence Pharmaceuticals

A75ba50c81a2e03495e48090d0c5083a-original

2afe5ad9fcdd811b34a2cf3c9e23a55d-original

5e2d904adc371e96a7acc0293cba5aa7-original

B444680683373c680b58a97072252092-original

5f4d816ba1a08eed1f53312271cdb260-original

6a3487e37b922479774d7fc3ebf2336d-original

8ed34837d1ea37af322c90c09d28ec47-original

Product

Confluence Pharmaceuticals is the exclusive licensee of a
clinically discovered, novel therapeutic treatment for core social and communication impairments in individuals suffering from Autism Spectrum Disorders (ASD) and Fragile X Syndrome (FXS). There is no FDA approved medication for these life-long impairments. According to published studies, the potential success of a therapeutic drug could reduce the cost of life-long care by as much as two-thirds.

Founders

You may be banned if you request references from people you don't know well. References will be required to write a comment. You cannot request references from investors.

Name

Email for confirmation

Mini-resume (160 characters max)
Always Show

Describe this person's previous achievements to a potential investor

Cancel
Boyd W. Sturdevant, Jr.

Chairman and Founder of Confluence Pharmaceuticals LLC
Craig Erickson

Founder, Lead Scientific Advisor, MD, Asst Professor Psychiatry, Chief -Christian Sarkine Autism Center, Chief- Fragile X Research Center, IU School of Medicine
Steve Johns

Co-Founder of Confluence Pharmaceuticals former CEO of eGIX, Inc. former CEO of ENS, Inc. former Managing Member of DSL Indiana Acquisitions LLC

Previous Investors

You may be banned if you request references from people you don't know well. References will be required to write a comment. You cannot request references from investors.

Name

Email for confirmation

Investment Amount

Mini-resume (160 characters max)
Always Show

Describe this person's previous achievements to a potential investor

Cancel
Boyd W. Sturdevant, Jr.

Chairman and Founder of Confluence Pharmaceuticals LLC
Craig Erickson

Founder & Lead Scientific Advisor. MD Psychiatry, Chief -Christian Sarkine Autism Center and Fragile X Research & Treatment Center, IU School of Medicine
Steve Johns

Co-Founder of Confluence Pharmaceuticals former CEO of eGIX, Inc. former CEO of ENS, Inc. former Managing Member of DSL Indiana Acquisitions LLC

Incubator

Incubated by

Cancel

Advisors

You may be banned if you request references from people you don't know well. References will be required to write a comment. You cannot request references from investors.

Name

Email for confirmation

Mini-resume (160 characters max)
Always Show

Describe this person's previous achievements to a potential investor

Cancel
Joe Muldoon

Board member at Confluence Pharmaceuticals LLC
Tim Parshall

Director at Pivotal Strategies LLC and Biotechnology Consultant
Bradley Fravel

Business Development Manager at the Indiana University Research & Technology Corporation. PhD Chemistry, MBA

References

You may be banned if you request references from people you don't know well. References will be required to write a comment. You cannot request references from investors.

Name

Email for confirmation

Mini-resume (160 characters max)
Always Show

Describe this person's previous achievements to a potential investor

Cancel
Jim Zaloudek

CFO at T2 Systems
Joe Muldoon

Board member at Confluence Pharmaceuticals LLC

Referrer

You may be banned if you request references from people you don't know well. References will be required to write a comment. You cannot request references from investors.

Name

Email for confirmation

Mini-resume (160 characters max)
Always Show

Describe this person's previous achievements to a potential investor

Cancel
Steve Johns

Co-Founder of Confluence Pharmaceuticals former CEO of eGIX, Inc. former CEO of ENS, Inc. former Managing Member of DSL Indiana Acquisitions LLC

“New confirmatory evidence that our drug is providing positive treatment response with corresponding change in biomarker levels in patients.”

27 days ago

5 Comments

17 Followers

Joe Muldoon Confluence is doing ground breaking work in an area of need led by a thoughtful and accomplished entrepreneur. I have a high degree of confidence in Steve's ability to move an enterprise forward and find it reassuring that they already have generated clinical data.

6 months ago

Jim Zaloudek I've worked with and had the pleasure of knowing Steve Johns for nearly twenty years. Throughout this time I have been, and continue to be, impressed with Steve's ability to guide and develop companies using both his analytical and leadership skills. As Steve applies these skills to Confluence, I have no doubt that it will succeed.

6 months ago

Steve Johns Unmet need market, Orphan Drug candidate, has significant human data in disease states.

1 month ago

2 comments are visible only to investors.

AngelList